8-[[1-([1,1'-biphenyl]-4-ylmethyl)-2-oxo-2-[(2-phenylethyl)amino]ethyl](phenylmethyl)amino]-8-oxo-octanoic acid ethyl ester | 1147752-20-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 8-[[1-([1,1'-biphenyl]-4-ylmethyl)-2-oxo-2-[(2-phenylethyl)amino]ethyl](phenylmethyl)amino]-8-oxo-octanoic acid ethyl ester
• 英文别名: Ethyl 8-[benzyl-[1-oxo-1-(2-phenylethylamino)-3-(4-phenylphenyl)propan-2-yl]amino]-8-oxooctanoate
• CAS: 1147752-20-2
• 化学式: C₄₀H₄₆N₂O₄
• 分子量: 618.816
• InChiKey: JTASBKCPTLYXEH-UHFFFAOYSA-N

物化性质

• 熔点：
  77-79 °C
• 沸点：
  804.5±65.0 °C(predicted)
• 密度：
  1.116±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  8.1
• 重原子数：
  46
• 可旋转键数：
  19
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  75.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-[[1-([1,1'-biphenyl]-4-ylmethyl)-2-oxo-2-[(2-phenylethyl)amino]ethyl](phenylmethyl)amino]-8-oxo-octanoic acid ethyl ester 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 以99%的产率得到8-[[1-([1,1'-biphenyl]-4-ylmethyl)-2-oxo-2-[(2-phenylethyl)amino]ethyl](phenylmethyl)amino]-8-oxo-octanoic acid
  参考文献：
  名称：

  Synthesis, Biological Evaluation, and Molecular Docking of Ugi Products Containing a Zinc-Chelating Moiety as Novel Inhibitors of Histone Deacetylases

  摘要：

  HDAC inhibitors show great promise for the treatment of cancer. AS part of a broader effort to explore the SAR of HDAC inhibitors, synthesis, biological evaluation, and molecular docking of novel Ugi products containing a zinc-chelating moiety are presented. One compound shows improved inhibitory potencies compared to SARA, demonstrating that hindered lipophilic residues grafted on the peptide scaffold of the alpha-aminoacylamides can be favorable in the interaction with the enzyme.

  DOI：

  10.1021/jm801529c
• 作为产物：
  描述：

  辛二酸氢乙酯 、 (9H-芴-9-基)甲基(吡咯烷-2-基甲基)氨基甲酸盐酸盐 、 苯乙基乙腈 、 苄胺 以 甲醇 为溶剂， 以43%的产率得到8-[[1-([1,1'-biphenyl]-4-ylmethyl)-2-oxo-2-[(2-phenylethyl)amino]ethyl](phenylmethyl)amino]-8-oxo-octanoic acid ethyl ester
  参考文献：
  名称：

  Synthesis, Biological Evaluation, and Molecular Docking of Ugi Products Containing a Zinc-Chelating Moiety as Novel Inhibitors of Histone Deacetylases

  摘要：

  HDAC inhibitors show great promise for the treatment of cancer. AS part of a broader effort to explore the SAR of HDAC inhibitors, synthesis, biological evaluation, and molecular docking of novel Ugi products containing a zinc-chelating moiety are presented. One compound shows improved inhibitory potencies compared to SARA, demonstrating that hindered lipophilic residues grafted on the peptide scaffold of the alpha-aminoacylamides can be favorable in the interaction with the enzyme.

  DOI：

  10.1021/jm801529c